Health

Concord Medical Announces Its Subsidiary's Application Filing for Potential Listing on The Stock Exchange of Hong Kong Limited

BEIJING, June 1, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensiv...

2022-06-02 04:15 2261

First AI to Refine Medical Coding by Exploring Therapeutic Data

SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Medical AI start-up Aesop Technology announced a new partnership that made their new product,DxPrime , available in the Olive Library . DxPrime provides physicians and ...

2022-06-02 01:22 2749

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the progress ...

2022-06-01 21:24 2500

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...

2022-06-01 21:00 2273

Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit

SHANGHAI, June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxu...

2022-06-01 19:49 1724

Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia

Australians living with migraine can now come 'out of the dark' with Avulux migraine lenses DANDENONG SOUTH, Australia, June 1, 2022 /PRNewswire/ -- The world's first clinically proven lens for migraine and light sensitivity management is now available through eye-care practitioners inAustralia....

2022-06-01 05:00 2337

USANA Signs Deal with Basketball New Zealand

Becomes Official Nutritional Supplement Supplier of Tall Blacks and Sky Sport Tall Ferns Squads SALT LAKE CITY, June 1, 2022 /PRNewswire/ -- For 30 years USANA, the Cellular Nutrition Company, has been a leader in its industry. With more professional and Olympic athletes trusting USANA with thei...

2022-06-01 02:22 2277

Toku Eyes, Developer of an AI Platform That Accurately Identifies Risk of Heart Attack Using an Eye Image, Expands to The US

With Toku Eyes' artificial intelligence platform, the eye is not only the window to the soul — it is now a window to the state of your health AUCKLAND, New Zealand, May 31, 2022 /PRNewswire/ -- Toku Eyes, the New Zealand -based developer of a multi-modal artificial intelligence platform for instan...

2022-06-01 00:00 2199

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 2045

Paramedic Training VR Nearly Doubles Students' Understanding of Teamwork in Medicine.

The Demonstration Test was Conducted for 663 Students at 14 Vocational Schools. 〜 The effect of VR was Confirmed in In-Hospital Care by Paramedics as its Importance is Increasing under the Revised Paramedic Act〜 TOKYO, May 31, 2022 /PRNewswire/ -- Jolly Good Inc. (based in Chuo-ku, Tokyo, Japan;...

2022-05-31 21:00 1530

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...

2022-05-31 20:00 1641

Volition Achieves CE Mark for Nu.Q® NETs Test

to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...

2022-05-31 20:00 3117

GBM AGILE OPENS TO PAXALISIB IN EUROPE

SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm inEurope. University Hospital Zurich...

2022-05-31 19:20 3201

Illuccix® Granted Transitional Pass-Through Payment Status

INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...

2022-05-31 19:00 1237

Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO

SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...

2022-05-31 17:56 714

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease

SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...

2022-05-31 11:30 1464

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...

2022-05-31 08:08 1325

Weiyun AI & Robotics Group Attended The Annual Meeting of AAO with Its AI SMILE New Breakthough, Shows Its Leading Power in Industrial AI of Dental Medicine

SHANGHAI, May 30, 2022 /PRNewswire/ -- On May 24, 2022, the 122nd Annual Meeting of the American Association of Orthodontists (AAO) came to a successful conclusion inMiami, USA. After two years of online annual meeting, this year, experts and scholars in the field of orthodontics from all over th...

2022-05-30 22:15 1700

The Global Fight Against Monkeypox: Zelixir Biotech Predicts Monkeypox Protein Structures

Abstract: China's biotech company Zelixir Biotech publishes 600+ protein structure predictions for the Monkeypox proteome SHANGHAI, May 30, 2022 /PRNewswire/ -- Zelixir Biotech announces it has predicted more than 600 structures and added functional annotations of proteins from monkeypox virus p...

2022-05-30 18:36 1911

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

NANJING, China, May 29, 2022  /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label...

2022-05-30 08:10 1814
1 ... 144145146147148149150 ... 273